00874 BAIYUNSHAN PHWatchlist
About BAIYUNSHAN PH Company
The company is a limited company approved by the National Economic System Reform Commission through Physical Reform  No. 139, initiated exclusively by Guangzhou Pharmaceutical Group Co., Ltd., restructured 8 traditional Chinese medicine manufacturers and 3 pharmaceutical trading enterprises, and established by means of initiation by investing in state-owned assets related to production and operation assets. It is mainly engaged in asset management, investment, development and financing, and is also engaged in the development and production of proprietary Chinese medicines, production of biological products, health medicines, and health drinks, as well as the wholesale, retail, import and export of traditional Chinese medicines, Western medicines and medical devices. The company is mainly engaged in (1) research and development, manufacturing and sales of proprietary Chinese and Western medicines, chemical APIs, natural medicines, biomedicine, and chemical raw drug intermediates; (2) wholesale, retail, import and export of Western medicines, traditional Chinese medicines and medical devices; (3) R&D, production and sales of major health products; and (4) investment in health industries such as medical services, health management, health care and old-age care. The company's main products are thirst quenching pills, Xia Sangju, Wuji Baifeng pills, Huayu recovery pills, honey refined chuanbei loquat cream, Qingkai Ling oral liquid, Xiaochai hu infusion, etc. The main products of Western medicine manufacturers are chemical preparations such as ceftriaxone, etc. The main products of prepackaged food manufacturers are Wang Laoji herbal tea, etc. During the reporting period, the Group and joint ventures obtained a total of 11 production approvals and passed 6 quality regulations for consistency evaluations. A total of 85 patents have been applied for, including 71 invention patents and 14 utility models; 60 authorized patents have been obtained, 40 invention patents have been granted, and 20 utility model patents have been granted.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) stock is up by a considerable 7.5% over the past week. Given that stock prices are usually aligned with a company's financial performance in t
Everbright Securities: Four Advantages of Accelerating Transformation and Upgrading of the Traditional Chinese Medicine Industry, Value Revaluation
The Zhitong Finance app learned that Everbright Securities published a research report saying that traditional Chinese medicine has rich clinical positioning and broad market space. Under medical reform policies and industry standards, quality, safety, and efficacy have continued to improve.
Changes in Hong Kong stocks | Modern Chinese Medicine Group (01643) rose by more than 4%, leading the Chinese medicine concept, favorable policies, and continued release of sectors with allocation value
Some traditional Chinese medicine concept stocks rose. As of press release, Modern Chinese Medicine Group (01643) rose 4.29% to HK$0.365; Zhongzhi Pharmaceutical (03737) rose 2.84% to HK$1.45; and Tong Ren Tang Technology (01666) rose 2.08% to HK$6.39.